Alkylation activity and molecular properties of two antineoplastic agents that utilise indometacin and a conjugate of aspirin with 2-aminonicotinic acid to transport nitrogen mustard groups

Drugs in R and D

Volumn 8, Issue 6, 2007, Pages 363-372

  Bartzatt, Ronald ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Alkylating agents, pharmacodynamics; Aspirin, pharmacodynamics; Cancer; Indometacin, pharmacodynamics

Indexed keywords

2 2 ACETOXYBENZOYLAMINONICOTINIC ACID; ACETYLSALICYLIC ACID; AMINE; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; INDOMETACIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OCTANOL; UNCLASSIFIED DRUG;

ALKYLATION; AQUEOUS SOLUTION; ARTICLE; BLOOD PH; COVALENT BOND; IONIZATION; PARTITION COEFFICIENT; PRIORITY JOURNAL; ROOM TEMPERATURE; SKIN PERMEABILITY; SOLUBILITY; THERMOSTABILITY;

EID: 35548976299     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708060-00004     Document Type: Article

References (44)

1. Nogrady T. Medicinal chemistry. New York: Oxford University Press, 1988
2. Gringauz A. Medicinal chemistry. New York: Wiley-VCH, 1997
3. Mattes W, Hartley J, Kohn K. DNA sequence selectivity of guanine N-7 alkylation by nitrogen mustards. Nucl Acids Res 1986; 14 (7): 2971-87
4. Workman P. Inhibition of human prostatic tumor acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustards. Chem Biol Interact 1978; 20 (1): 103-12
5. Peiper R, Erickson L. DNA adenine adducts induced by nitrogen mustards and their role in transcription termination in vitro. Carcinogenesis 1990; 11: 1739-46
6. Burchenal J, Burchenal JR, Johnston S. Chemotherapy of leukemia: III. Further studies on the effect of nitrogen mustards and related compounds on transmitted mouse leukemia. Cancer 1951; 4: 353-6
7. Sulik R. Treatment of malignancies of the lymphoid and reticular systems by a new nitrogen mustard derivative. Arzneimittel-Forschung 1958; 8: 360-1
8. Sampey J. Nitrogen mustards in the management of Hodgkin's disease and the leukemias. J S C Med Assoc 1963; 59: 272-4
9. Pop F, Roth S, Kirby J. Synthesis of potential anticancer agents: IX. Some cycloalkyl mustards and related compounds. J Med Chem 1963; 6: 83-6
10. Elderfield R, Roy J. Synthesis of potential anticancer agents: XVII. Nitrogen mustards from 6-substituted coumarins. J Med Chem 1967; 10 (5): 918-21
11. Keitel R, Poege A. Testing of some nitrogen mustard compounds for cytostatic activity by a screening test. Archiv Fuer Geschwulstforschung 1975; 43 (2): 168-71
12. Mathur I, Gupta H, Gupta SK. Antitumor activity of certain N-arylmethyl nitrogen mustards in Walker carcinosarcoma 256 and lymphocytic leukemia P 388. Indian Vet Med J 1977; 1 (1): 11-9
13. Bacherikov V, Chou T, Dong H, et al. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis, and antitumor evaluation. Bioorg Med Chem Lett 2001 Sep; 14 (18): 4719-22
14. Conners T, Jenney A, Warwick G, et al. Factors influencing the sensitivity of tumors to nitrogen mustards. Isotop Exp Pharmacol 1965; 438
15. Sun D, Hurley L. Analysis of the monoalkylation and cross-linking sequence specificity of bizelesin, a bifunctional alkylation agent related to (+)-CC-1065. J Am Chem Soc 1993; 115 (14): 5925-33
16. Paz M, Sigurdsson S, Hopkins P. Monoalkylation of DNA by reductively activated FR66979. Bioorg Med Chem 2000; 8 (1): 173-9
17. Palom Y, Kumar G, Tang LQ, et al. Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chem Res Toxicol 2002; 15 (11): 1398-406
18. Osborne R, Lawley P. Alkylation of DNA by melphalan with special reference to adenine derivatives and adenine-guanine crosslinking. Chem Biol Interact 1993; 89 (10): 49-60
19. Kim Y, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003; 139 (2): 165-73
20. Chinn D, Chow S, Kim Y, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol 1999; 43 (5): 951-8
21. Ventafridda V, De Conno F, Peneral A, et al. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Int Med Res 1990; 18 (1): 21-9
22. Ding, X, Tong W, et al. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000; 20 (4): 2625-31
23. Morgan G, Vainio H. Non-steroidal anti-inflammatory drugs and cancer prevention: a review of the recent evidence. Curr Top Pharmacol 2002; 6: 25-39
24. Gardiner P, Gillmer J. The medicinal chemistry implications of the anticancer effects of aspirin and other NSAIDs. Mini-Rev Med Chem 2003; 3 (5): 461-70
25. Lupulescu A. Prostaglandins: their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 1996; 54 (2): 83-94
26. Greenberg E, Baron J, Freeman D, et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85 (11): 912-6
27. Goeke M. COX-2 independent antiproliferation action of acetyl-salicylic acid in human colon cancer cells. Eur J Clin Invest 2002; 32 (11): 793-4
28. Hull M, Gardner S, Hawcroft G. Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer. Cancer Treat Rev 2003; 29 (4): 309-20
29. Blake J. Chemoinformatics: predicting the physiochemical properties of drug-like molecules. Curr Opin Biotechnol 2000; 11: 104-7
30. Gareth T. Medicinal chemistry. New York: John Wiley and Sons, 2000
31. Gringauz A. Medicinal chemistry. New York: John Wiley and Sons, 1997
32. Silverman R. The organic chemistry of drug design and drug action. San Diego (CA): Academic Press, 1992
33. Hansch C, Leo A. Exploring QSAR. Washington (DC): American Chemical Society, 1995
34. Lipinski C, Lombardo F, Dominy B, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25
35. Clark D. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena: 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999; 88 (8): 815-20
36. Kelder J, Grootenhuis P, Bayada D, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999; 16 (10): 1514-9
37. Bartzatt R, Kasher L. Synthesis of aromatic nitrogen mustard agents and analysis of their alkylation activity at physiological pH and temperature. Physiol Chem Phys Med NMR 2002; 34: 103-17
38. Pratt W, Ruddon R, Ensminger W, et al. The anticancer drugs. New York: Oxford University Press, 1994
39. Kosaka R. Pharmaceuticals and drinks containing papain and citric acid for treatment of gynecological diseases. Japan Kokai Tokkyo Koho 1986: 1-3
40. Dornberger K. Investigation on the potential antineoplastic constituents of Physalis alkekengi L. Var franchatii Mast. Pharmazie 1986; 41 (4): 265-8
41. Mandronis K. Glyoxalic and citric acid preparation used for long life and cosmetic use, or for curing cancer, AIDS, and any pathological conditions. Athens: Patent Contents, 2003
42. Zakem M, Davis B, Adelstein J, et al. Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M). Cancer 1986; 58 (12): 2611-6
43. Rassidakis G, Medeiros J, McDonnell T, et al. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res 2002; 8 (2): 488-93
44. Straus D, Myers J, Koziner B, et al. Combination chemotherapy for the treatment of Hodgkin's disease in relapse: results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (adriamycin), bleomycin, and vinblastine (ABV). Cancer Chemother Pharmacol 1983; 11 (2): 80-5